Compare KREF & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KREF | VALN |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.7M | 495.5M |
| IPO Year | N/A | 2021 |
| Metric | KREF | VALN |
|---|---|---|
| Price | $7.15 | $5.40 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $7.88 | ★ $15.50 |
| AVG Volume (30 Days) | ★ 964.6K | 18.9K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 6.49% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $545.92 | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.25 | $5.04 |
| 52 Week High | $9.98 | $12.25 |
| Indicator | KREF | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 56.48 | 47.87 |
| Support Level | $6.74 | $5.10 |
| Resistance Level | $7.45 | $5.52 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 79.17 | 63.98 |
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.